Objective: Epilepsy is highly prevalent among patients with intellectual disability (ID), and seizure control is often difficult. Identification of the underlying etiology in this patient group is important for daily clinical care. We assessed the diagnostic yield of whole exome sequencing (WES). In addition, we evaluated which clinical characteristics influence the likelihood of identifying a genetic cause and we assessed the potential impact of the genetic diagnosis on (antiepileptic) treatment strategy. Methods: One hundred patients with both unexplained epilepsy and (borderline) ID (intelligence quotient ≤ 85) were included. All patients were evaluated by a clinical geneticist, a (pediatric) neurologist, and/or a specialist ID physician. WES analysis was performed in two steps. In step 1, analysis was restricted to the latest versions of ID and/or epilepsy gene panels. In step 2, exome analysis was extended to all genes (so-called full exome analysis). The results were classified according to the American College of Medical Genetics and Genomics guidelines. Results: In 58 patients, the diagnostic WES analysis reported one or more variant(s).
| INTRODUCTION
Epilepsy is a neurological condition that is particularly common in patients with intellectual disability (ID). The prevalence of epilepsy among patients with ID is estimated to be around 22.2% (95% confidence interval = 19.6-25.0), with prevalence rates increasing with severity of ID. 1 These findings contrast with the rates of around 1% that are reported for the general European population. 2 There is increased interest in understanding ID-and epilepsy-associated (neuropsychiatric) health risks from an etiological perspective. This interest is partly due to advanced genomic technologies now being able to identify a cause in an increasing proportion of patients with ID and in patients with epilepsy. These new diagnoses provide opportunities to delineate cause-specific characteristics and may lead to a greater understanding of comorbidities and prognosis. Furthermore, establishing a genetic diagnosis may even influence treatment choices, as has been demonstrated in patients with variants in the SCN1A, SCN8A, SLC2A1, and POLG genes.
Ideally, a recognizable phenotype will lead to the suspicion of a specific clinical diagnosis followed by confirmation with a specific diagnostic test, such as Sanger sequencing of the associated gene. ID and epilepsy, however, are extremely clinically and genetically heterogeneous, which challenges the search for an etiological diagnosis. In addition, the clinical spectrum of a specific genetic defect can be very broad. 3 Before the introduction of whole exome sequencing (WES), an etiological diagnosis could be established in about 40% of patients with previously unexplained developmental delay or ID, by using clinical examination and subsequent specific (DNA) diagnostic tests, high-resolution genome-wide chromosomal analysis, and screening for metabolic disorders. [4] [5] [6] Recent studies have demonstrated the efficacy of detecting genetic alterations using a next generation sequencing panel approach or WES [7] [8] [9] [10] [11] [12] in patients with epilepsy. Some of these studies also included patients with ID. The diagnostic yield varied between 30% and 70%. [7] [8] [9] [10] [11] [12] In this study, we specifically focused on patients with both epilepsy and (borderline) ID. This focus is in line with the white paper on the medical and social needs of people with epilepsy and intellectual disability of the International League Against Epilepsy 13 that recommended action in investigation of etiology and mentioned that specific attention is needed to different aspects concerning adequate antiepileptic treatment in this population.
We assessed the diagnostic yield in this group and evaluated which clinical characteristics determined the likelihood of identifying a genetic diagnosis. In addition, we discuss the potential consequences of the newly established genetic diagnosis for the treatment strategy.
| MATERIALS AND METHODS

| Study population
We retrospectively included 100 consecutive patients, both adults and children, with both epilepsy and (borderline) ID with an unknown cause. Inclusion started in January 2016. Enrollment was based on the clinical referral to our multidisciplinary outpatient clinic at the Academic Center for Epileptology at Kempenhaeghe, Heeze, The Netherlands or Maastricht University Medical Center, Maastricht, the Netherlands. All patients were evaluated by a clinical geneticist and a (pediatric) neurologist and/or specialist ID physician with specific expertise in this group of patients.
The study was assessed by the ethical committee of Maastricht University Medical Center (16-2-248.1) and was found to have no obligations regarding the Dutch Act on Medical Research in People.
| Inclusion criteria
To be enrolled in this study, a patient had to meet all of the following criteria:
Unexplained ID according to International Classification of Diseases, 10th revision 14 and Diagnostic and Statistical Manual of Mental Disorders, 5th edition, 15 defined as having both reduced intellectual functioning (intelligence quotient < 70) and impaired adaptive abilities to cope with the daily demands of the social environment, manifesting during the developmental period of an individual. In addition, we included patients with borderline intellectual functioning (intelligence quotient = 70-85).
14 Unexplained etiology of (active) epilepsy, according to the International League Against Epilepsy classification
Key Points
• The diagnostic yield of diagnostic exome sequencing in patients with both intellectual disability and epilepsy in our study is at least 25% • In 40% of the patients with a (likely) pathogenic variant, the diagnosis might be relevant for daily care and treatment strategy • The described variants of uncertain significance in (candidate) genes warrant validation in future studies of Scheffer et al. 16 This could be present as an associated feature; it was not necessary to have epilepsy as a main phenotypic feature. Parents and/or legal representative consented to anonymous inclusion of the clinical and molecular data for research purposes.
By not excluding patients with a positive family history, we were also able to identify focal familial forms of epilepsy. A specialized neurologist (H.J.S.) rated the brain magnetic resonance imaging findings into three categories: normal, abnormal without epileptogenic focus, and abnormal with epileptogenic focus. The allocation was based on the likelihood that the lesions were responsible for the seizures presented in the individual patient. Therefore, if a lesion could, based on the magnetic resonance imaging location or characteristics, theoretically be epileptogenic but could not be linked to the seizure type of this specific patient, it was rated as abnormal but not epileptogenic.
| Data collection
| Study procedures
Diagnostic WES was performed in all patients who remained undiagnosed by previous targeted DNA diagnostic tests (ie, Sanger sequencing) on clinical indication. In most patients, chromosomal abnormalities were excluded in prior diagnostic evaluations. Recently, copy number variation analysis in WES data for the detection of chromosomal abnormalities became available. 17 Therefore, genome-wide chromosomal analysis was not performed in all cases prior to WES. Diagnostic exome sequencing was done at the Departments of Human Genetics of the Radboud University Medical Center Nijmegen and Maastricht University Medical Center, Maastricht, The Netherlands and performed essentially as described previously. 18 It was preferentially done by a trio-based approach (patient + both parents) to facilitate the interpretation of variants.
In a first step of WES, only variants in known epilepsy (and/or ID) genes were considered by using a filter for specific panels in all patients (latest versions of epilepsy gene panel 19 and/or ID gene panel 20 ) . The choice of a specific panel was based on clinical evaluation and indication; in nearly half of the patients (49/100) we opted for the epilepsy panel, as epilepsy was thought to be the primary/initial disorder. In 34 of 100 patients, both the epilepsy and ID panels were analyzed. In the remaining patients, only the ID gene panel was analyzed first, because in these cases, ID was thought to be the main feature. However, there is a substantial overlap between the ID and epilepsy gene panels (88.7% of epilepsy candidate genes are covered in the ID panel, and 21.2% of ID candidate genes are covered in the epilepsy panel).
If the panel analysis did not reveal a pathogenic variant, the diagnostic exome sequencing was extended to the full exome; variants in all other genes were considered. Fullexome analysis could only be performed among patients of whom parents or legal representatives provided written informed consent. Validation and segregation analysis of putative causative variants were done by Sanger sequencing.
| Interpretation of variants
By the laboratories of genome diagnostics, variants were classified on the basis of the existing Dutch guidelines for evaluation of the pathogenicity of variants 21 and the interpretation of sequence variants according to the American College of Medical Genetics and Genomics (ACMG) guidelines. 22 The ACMG guidelines define 28 criteria (each with an assigned code) that address evidence such as population data, case-control analyses, functional data, computational predictions, allelic data, segregation studies, and de novo observations. Each code is assigned a weight (stand-alone, very strong, strong, moderate, or supporting) and direction (benign or pathogenic). The combination of these evidence codes leads to the following five classifications: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign. 22 
| Statistical analyses
Direct associations between clinical characteristics and the presence of a (likely) pathogenic variant were examined using the Pearson chi-square test or Fisher's exact test in case of low sample size in particular categories. We chose not to correct for multiple testing (Bonferroni) in this clinically orientated and relatively small study. The analyses were performed using SPSS Statistics version 23 software (IBM).
| RESULTS
Demographical and clinical characteristics of all patients with epilepsy and ID (N = 100) are displayed in Table 1 . Previous etiological research, such as DNA and/or chromosomal examination or a metabolic screening, was available in 96% of patients. An overview of the type of previous etiological investigations, related to the diagnostic yield found in this present study, is presented in Table 2 .
| WES analyses
In 66 of the 100 patients, WES analysis was trio-based. In the remaining 34, WES analysis was done in the index only, due to lack of consent or availability of DNA of both parents, necessary for the full exome analysis. If indicated and possible, additional segregation analysis in other family members was performed, such as in a single available parent, and other family members, both affected and unaffected. Initially, in 49 of the 100 patients analysis was restricted to the epilepsy gene panel 19 and in 17 of the 100 patients the analysis was restricted to the ID panel. 20 In 34 of the 100 patients, both the epilepsy and ID gene panels were analyzed. Extension of the analysis to the full exome was performed if the ID and/or epilepsy gene panels did not detect a (likely) pathogenic variant (56/100 patients), consent for full exome analysis was given, and DNA of both parents was available. We summarized the process of analysis in a flowchart (Figure 1 ).
| Diagnostic yield
In 59 patients, one or more genetic variant(s) of interest were reported in the WES analysis, with either dominant (n = 51, mostly de novo), recessive (n = 2), or X-linked (n = 6) inheritance. In 25 of the 100 patients, these were classified as (likely) pathogenic, in 24 cases as VUS, and in the remaining cases the identified variant was classified as (likely) benign. See Table 3 for an overview of the diagnostic yield, including the genes involved. (Likely) pathogenic variants were found by panel analyses (epilepsy and/ or ID panel) in 72% and the remaining 28% by additional full exome analysis. In four of nine patients who had WES with analysis of both the epilepsy and ID panels, a pathogenic variant in a specific ID gene that is not covered by the epilepsy panel was identified. A complete overview of the likely pathogenic variants and VUS/VUS in candidate genes is presented in Tables S1 and S2.
| Potential clinical indicators of pathogenic variants
The analyses revealed that most clinical characteristics were not related to the WES outcome (see Table 4 ). The exception was that pathogenic variants were significantly more prevalent among patients with epilepsy originating after childhood (P = 0.001).
Neuropsychiatric comorbidities were present in 62% of patients, with autism spectrum disorders being most frequently diagnosed (22%). In addition, the presence of such comorbidities was also significantly related to detection of a causal variant with WES (P = 0.046). More specifically, affective symptoms (ie, depressive symptoms or anxiety) were significantly more prevalent in those with a pathogenic variant than in those without. For all other characteristics, no significant relationship to the outcome of WES was observed.
| Relevant findings for daily clinical care
In five patients (20%) with a (likely) pathogenic variant, we found variants with a potential consequence for antiepileptic drug treatment and clinical approach, that is, SCN1A (3×) and SCN8A (2×). In Patient 4 (Table S1 ), in whom a SCN1A encephalopathy was not considered before this WES study, lamotrigine was reduced, and preliminary results show a positive effect, especially on the patient's behavior and mood. In another five (20%) patients of the (likely) pathogenic group, we found variants with a possible consequence for daily clinical care, that is, in the genes CACNA1A, GRIN2A, SLC13A5, and SLC6A1 (2×). Whereas apart from SCN1A and SCN8A, no direct change in treatment strategy is to be expected yet, this might change in the future.
| DISCUSSION
In the current study of 100 patients with both epilepsy and ID, we identified a (likely) pathogenic variant in 25 and a VUS with possible relation to the phenotype in another 24. Eight patients had a VUS in a potential candidate gene for a phenotype with epilepsy and ID (such as SPRED2, GLRA2, and CTNNA2).
Yields in previous diagnostic cohort studies varied from 30% to 70% [7] [8] [9] [10] [11] [12] and depended on the diagnostic strategy.
Several studies used targeted next generation sequencing approaches with a fixed number of genes included. The number of genes varied highly, and in addition, the filtering and interpretation of variants differed among the various studies. Therefore, the diagnostic yields of the studies are difficult to compare. In our study, the ACMG guidelines for classification of the variants were used. In these guidelines, the clinical information has a relatively low weight in the interpretation of variants. We identified several variants (variants in TSEN54, PGAP3, CLCN4, NBEA, and TCF20, see Table S2 ) that would be classified as likely pathogenic from a clinical point of view but do not strictly fulfill the criteria for pathogenicity according to the ACMG guidelines, for example, because functional evidence is lacking. If we would add these variants to the total yield, this would sum up to 30%. Therefore, application of the ACMG criteria will likely have led to an underestimation of the clinical diagnostic value. However, it is inevitable to use stringent criteria as in the ACMG guidelines when making use of untargeted testing of large numbers of genes, rather than specifically testing one or a small number of genes based on a distinct phenotype. The yield in this study may have been even higher if all patients had a full trio-based exome analysis, but as in regular daily clinical practice, full exome analysis is not always possible due to lack of consent or availability of DNA of one or both of the parents.
In our cohort, clinical characteristics of patients, such as congenital anomalies or dysmorphic features, seemed mostly unrelated to the WES outcome. This indicates that patient characteristics cannot predict the likelihood that WES will identify a causal variant for the phenotype. Therefore, genetic diagnostic investigation by WES should be considered in all patients with both unexplained epilepsy and ID. A (likely) pathogenic variant was more prevalent in the group of patients with a later onset of epilepsy (after childhood). This observation is possibly due to our multidisciplinary clinic being situated in a tertiary epilepsy center. In this setting, those patients with an obvious epilepsy syndrome originating early in life, such as Dravet syndrome or epileptic encephalopathy with continuous spike and wave during sleep, are likely to be diagnosed at an earlier stage by targeted DNA diagnostic testing.
Remarkably, the number of patients with an "unknown" epilepsy type is notably high in our cohort. This could be partly explained by the average age of the patients at the time of study (24 years) in combination with the finding that most patients suffered from epilepsy from an early age and the seizure semiology changed throughout the years.
Although there is a substantial overlap between the epilepsy and ID gene panels, it is important to realize that several genes that could potentially be associated with both phenotypes are not necessarily included in both panels. For example, epilepsy can be part of the phenotype in a small subset of the patients with a specific mutation but is not recognized as a distinctive feature of this mutation. In four cases, (likely) pathogenic variants were identified in specific ID genes that are not covered by the epilepsy panel, and thus would have been missed if only the epilepsy panel was analyzed (eg, Patient 8 in Table S1 ). Conversely, we could have missed some of the variants when the analysis would have been restricted to the ID panel, for example a variant in SLC6A1, as this gene was not included in the ID gene panel (see Patient 24 in Table S1 ). It is also possible that the epilepsy and ID have separate causes in a specific individual, which can be missed if the analysis is restricted to one of both panels. We therefore recommend analysis of both panels, especially when a full exome analysis is not possible or not consented to by the parents/legal representative(s). We would not recommend analysis of the total exome immediately, because of the chance of unsolicited findings and higher chance of detecting variants of uncertain significance, and because a substantial number of patients will be diagnosed by the panel analyses.
Although we did not find any unsolicited findings in our cohort, full exome analysis is accompanied by an increased risk of 1%-2% for possible unsolicited findings and has a higher incidence of identification of unknown variants. Despite this, full exome analysis also has the advantage of the possible identification of novel or very recently discovered new genes for phenotypes with both ID and epilepsy that have not yet been included in current panel releases. In addition, full exome analysis allows a genome-wide analysis for chromosomal copy number variations and can thereby largely replace separate chromosomal analysis by array analysis. 23 T A B L E 1 (Continued) Characteristics n Disruptive/impulse control 13
Automutilation 3
Sleep-wake disorder 1 AED, antiepileptic drug; ASD, autism spectrum disorder; ID, intellectual disability; KD, ketogenic diet; MRI, magnetic resonance imaging; VNS, vague nerve stimulation; WES, whole exome sequencing. Despite the high yield of WES, it is important to realize that not all genetic causes of ID and epilepsy can be detected by this approach. WES will not detect trinucleotide repeats, as for example a CGG repeat expansion in the FMR1 gene in fragile X syndrome. In addition, balanced chromosomal rearrangements, such a ring chromosome 20 causing epilepsy, will not be detected using WES.
T A B L E 2 Previous etiological investigations compared to current whole exome sequencing results
Previous
This study is in line with the report "Listening for a Change" that was published by the International League Against Epilepsy Task Force on ID and the International Bureau for Epilepsy. 13, 24 To optimize the genetic investigations as well as communication, all studies were performed and evaluated in a multidisciplinary setting at an outpatient clinic that is dedicated to the care of patients with ID and epilepsy. In line with the philosophy of this guideline, we also considered and discussed whether the outcome of the genetic studies might potentially guide treatment options (in the future) of the individual patient. For 10 of the 25 patients (40%) with a (likely) pathogenic variant, the new diagnosis might have, according to the literature, a consequence for antiepileptic treatment. For example, in patients with Dravet syndrome due to an SCN1A mutation, there is evidence for the efficacy of stiripentol, based on two randomized controlled trials (Chiron et al 25 and STICLO study group [not published]), and there are medications to avoid, especially lamotrigine, phenytoin, and carbamazepine. 26 There is also literature suggesting that patients with SCN8A gain of function mutations have been shown to respond well to high-dose phenytoin. 27 In addition, there is literature suggesting that for some patients with a GRIN2A missense mutation, the N-methyl-D-aspartate receptor blocker memantine should be considered 28, 29 and that finding a mutation in the CACNA1A,
30
SLC13A5, 31,32 andSLC6A1 (2×) 33 genes might guide antiepileptic treatment options in the future. For these genes, additional functional studies in a diagnostic setting will be necessary to delineate the full potential of personalized medicine. Our study highlights the diagnostic relevance of WES for patients with both epilepsy and ID in clinical practice. Prior studies have been performed in a more selected group, that is, patients with epileptic encephalopathy, and with different inclusion criteria, for example, exclusion of patients with positive family history and/or structural anomalies. 12, 34 Because of the design of our study, we also identified patients with ID syndromes with epilepsy as an associated feature, but not necessary as the main feature. In addition, by not excluding patients with a positive family history, we were also able to identify focal familial forms of epilepsy, such as epilepsy caused by a mutation in DEPDC5. A limitation of our study is that our population was biased not only by the referral bias to a tertiary clinic but also by an almost exclusively Caucasian study population. However, our study also demonstrates that implementing WES diagnostics might be relevant for the treatment strategy in this complex population.
The VUS that we identified in novel candidate genes for epilepsy and ID such as GLRA2, SAMD4A, and MACF1 warrant validation in future studies, such as functional studies and studies in larger patient groups, to confirm that these candidate genes are associated with epilepsy and ID and further delineate the related phenotype.
